52 studies found for:    vismodegib
Show Display Options
Rank Status Study
1 Active, not recruiting Trial Comparing the Effects of Intermittent Vismodegib Versus Photodynamic Therapy in Patients With Multiple Basal Cell Carcinomas
Conditions: Basal Cell Nevus Syndrome;   Gorlin's Syndrome
Interventions: Drug: GDC-0449;   Procedure: Aminolevulinic acid %20 topical solution + blue light
2 Recruiting Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
Conditions: Locally Advanced Basal Cell Carcinoma;   Skin Cancer;   Cutaneous Malignancy
Interventions: Drug: Vismodegib;   Radiation: Radiation therapy
3 Not yet recruiting A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy
Condition: Prostate Cancer
Intervention: Drug: Vismodegib
4 Recruiting Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway
Conditions: Histologically Confirmed Medulloblastoma;   Activation of the Sonic Hedgehog (SHH) Pathway
Interventions: Drug: vismodegib;   Drug: Temozolomide
5 Unknown  Vismodegib for Treatment of Basal Cell Carcinoma
Condition: Basal Cell Carcinoma
Interventions: Drug: Vismodegib;   Drug: Placebo
6 Completed
Has Results
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Vismodegib 150 mg;   Drug: Placebo to vismodegib;   Drug: Bevacizumab;   Drug: Modified FOLFOX;   Drug: FOLFIRI
7 Active, not recruiting Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: vismodegib;   Other: pharmacological study;   Other: laboratory biomarker analysis
8 Completed
Has Results
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission
Condition: Ovarian Cancer
Interventions: Drug: Vismodegib 150 mg;   Drug: Placebo to vismodegib
9 Recruiting Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia
Conditions: Diffuse Large B-cell Lymphoma;   "Indolent" Non-hodgkin Lymphoma;   Primary Central Nervous System Lymphoma;   Chronic Lymphocytic Leukemia
Intervention: Drug: Vismodegib
10 Recruiting Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma
Condition: Pontine Glioma
Intervention: Drug: Vismodegib
11 Completed
Has Results
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
Condition: Basal Cell Carcinoma
Intervention: Drug: Vismodegib
12 Active, not recruiting Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention
Condition: Basal Cell Carcinomas
Interventions: Drug: Vismodegib;   Drug: Placebo
13 Active, not recruiting Evaluation of Food Effect on Pharmacokinetics of Vismodegib
Condition: Malignant Neoplasm
Interventions: Drug: vismodegib;   Other: pharmacological study
14 Active, not recruiting
Has Results
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma
Condition: Basal Cell Carcinoma
Intervention: Drug: Vismodegib 150 mg
15 Active, not recruiting Vismodegib in Treating Patients With Basal Cell Carcinoma
Conditions: Basal Cell Carcinoma of the Skin;   Recurrent Skin Cancer
Interventions: Drug: vismodegib;   Procedure: Mohs surgery
16 Active, not recruiting Vismodegib in Treating Patients With Advanced Chondrosarcomas
Condition: Chondrosarcoma
Interventions: Drug: vismodegib;   Other: laboratory biomarker analysis
17 Active, not recruiting Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
Condition: Recurrent Childhood Medulloblastoma
Interventions: Drug: vismodegib;   Other: pharmacological study;   Other: laboratory biomarker analysis
18 Active, not recruiting Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
Condition: Adult Medulloblastoma
Interventions: Drug: vismodegib;   Other: pharmacological study
19 Active, not recruiting Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer
Conditions: Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: vismodegib;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis
20 Active, not recruiting Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: vismodegib;   Drug: sirolimus;   Procedure: positron emission tomography;   Procedure: computed tomography;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Radiation: fludeoxyglucose F 18

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years